The trifunctional mAb catumaxomab targets CD3 on T-cells, Fc-receptors on innate immune cells, and EpCAM on tumor cells, and it is heterogeneously overexpressed in epithelial cancers, including EOC. The gene discussed is EPCAM; the disease is neoplasm.